Journal article · 2023 · Open access

Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database

Ryo Inose, Arisa Nakamura, R. Omi, Shujiro Takeno, Yuichi Muraki

International Journal of Clinical Pharmacology and Therapeutics, 61(10), 430–436 · Published 14 August 2023 · DOI 10.5414/cp204372

Open PDFView at the publisherCite this paper

In brief

“Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database” is a 2023 journal article by Ryo Inose and 4 co-authors, published in International Journal of Clinical Pharmacology and Therapeutics. OpenAlex counts 9 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at PubMed Central.

Citations
9
Most cited in
2025 (4)
Field-weighted impact
1.50
References
7
Authors
5

Abstract

OBJECTIVE: The risk of malignancy in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX) and biological disease-modifying antirheumatic drug (bDMARD) combination therapy is unknown. This study aimed to clarify the incidence of malignancy and the recommended monitoring period in patients receiving this combination therapy. MATERIALS AND METHODS: A retrospective, observational study based on a large Japanese medical claims database was conducted between April 2013 and February 2020. Patients with RA were classified into MTX-alone and combination therapy groups, and the standardized incidence rates (SIR) of malignancy were calculated. The time of onset of malignancy in both groups was calculated. RESULTS: In total, 2,052 patients received MTX-alone and 782 received combination therapy. The incidence of malignant lymphoma was significantly higher with MTX-alone therapy (SIR: 6.09, 95% confidence interval (CI): 1.58 - 10.61) and combination therapy (SIR: 20.86, 95% CI: 8.53 - 33.19) than in the general Japanese population. Furthermore, the combination therapy had a significantly higher risk of malignant lymphoma than the MTX-alone therapy (adjusted odds ratio: 4.27, 95% CI: 1.64 - 11.12). The median time from MTX prescription to the onset of malignant lymphoma was 3.58 years (interquartile range (IQR): 2.00 - 5.34 years) for MTX-alone and 3.42 years (IQR: 1.25 - 4.92 years) for combination therapy. CONCLUSION: year after initiating MTX therapy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Inose, R., Nakamura, A., Omi, R., Takeno, S., & Muraki, Y. (2023). Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database. International Journal of Clinical Pharmacology and Therapeutics, 61(10), 430–436. https://doi.org/10.5414/cp204372

MLA 9

Inose, Ryo, et al. “Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database.” International Journal of Clinical Pharmacology and Therapeutics, vol. 61, no. 10, 2023, pp. 430–436. https://doi.org/10.5414/cp204372.

Chicago

Inose, Ryo, Arisa Nakamura, R. Omi, Shujiro Takeno, and Yuichi Muraki. 2023. “Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database.” International Journal of Clinical Pharmacology and Therapeutics 61 (10): 430–436. https://doi.org/10.5414/cp204372.

Harvard

Inose, R. et al. (2023) ‘Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database’, International Journal of Clinical Pharmacology and Therapeutics, 61(10), pp. 430–436. doi:10.5414/cp204372.

IEEE

R. Inose, A. Nakamura, R. Omi, S. Takeno, and Y. Muraki, “Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database,” International Journal of Clinical Pharmacology and Therapeutics, vol. 61, no. 10, pp. 430–436, 2023, doi: 10.5414/cp204372.

BibTeX

@article{inose2023risks,
  title     = {{Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database}},
  author    = {Inose, Ryo and Nakamura, Arisa and Omi, R. and Takeno, Shujiro and Muraki, Yuichi},
  journal   = {International Journal of Clinical Pharmacology and Therapeutics},
  year      = {2023},
  volume    = {61},
  number    = {10},
  pages     = {430--436},
  doi       = {10.5414/cp204372},
  url       = {https://doi.org/10.5414/cp204372}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202311
202411
202544
202633

Its field-weighted citation impact is 1.50: it has been cited 1.50 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • methotrexate
  • lymphoma
  • cancer risk
  • combination therapy
  • biologic DMARDs
  • disease-modifying antirheumatic drugs
  • standardized incidence rate

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Inose, R., Nakamura, A., Omi, R., Takeno, S., & Muraki, Y. (2023). Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database. International Journal of Clinical Pharmacology and Therapeutics, 61(10), 430–436. https://doi.org/10.5414/cp204372

How many times has this paper been cited?

9 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at PubMed Central: sign in and open the PDF from this page.

Who wrote this paper?

Ryo Inose, Arisa Nakamura, R. Omi, Shujiro Takeno, Yuichi Muraki.

What is the DOI of this paper?

10.5414/cp204372, permanently at https://doi.org/10.5414/cp204372. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.